vs
Loar Holdings Inc.（LOAR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Loar Holdings Inc.的1.6倍（$207.3M vs $131.8M），Loar Holdings Inc.净利率更高（9.5% vs -62.0%，领先71.5%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 19.3%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 19.8%）
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
LOAR vs RARE — 直观对比
营收规模更大
RARE
是对方的1.6倍
$131.8M
营收增速更快
RARE
高出6.6%
19.3%
净利率更高
LOAR
高出71.5%
-62.0%
两年增速更快
RARE
近两年复合增速
19.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $131.8M | $207.3M |
| 净利润 | $12.5M | $-128.6M |
| 毛利率 | 52.1% | — |
| 营业利润率 | 18.0% | -54.7% |
| 净利率 | 9.5% | -62.0% |
| 营收同比 | 19.3% | 25.9% |
| 净利润同比 | 239.5% | 3.5% |
| 每股收益（稀释后） | $0.13 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LOARRARE
| Q4 25 | $131.8M | $207.3M | ||
| Q3 25 | $126.8M | $159.9M | ||
| Q2 25 | $123.1M | $166.5M | ||
| Q1 25 | $114.7M | $139.3M | ||
| Q4 24 | $110.4M | $164.6M | ||
| Q3 24 | $103.5M | $139.5M | ||
| Q2 24 | $97.0M | $147.0M | ||
| Q1 24 | $91.8M | $108.8M |
净利润LOARRARE
| Q4 25 | $12.5M | $-128.6M | ||
| Q3 25 | $27.6M | $-180.4M | ||
| Q2 25 | $16.7M | $-115.0M | ||
| Q1 25 | $15.3M | $-151.1M | ||
| Q4 24 | $3.7M | $-133.2M | ||
| Q3 24 | $8.7M | $-133.5M | ||
| Q2 24 | $7.6M | $-131.6M | ||
| Q1 24 | $2.2M | $-170.7M |
毛利率LOARRARE
| Q4 25 | 52.1% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 53.8% | — | ||
| Q1 25 | 52.1% | — | ||
| Q4 24 | 48.9% | — | ||
| Q3 24 | 51.1% | — | ||
| Q2 24 | 49.0% | — | ||
| Q1 24 | 48.4% | — |
营业利润率LOARRARE
| Q4 25 | 18.0% | -54.7% | ||
| Q3 25 | 22.9% | -106.9% | ||
| Q2 25 | 22.2% | -64.8% | ||
| Q1 25 | 22.8% | -102.6% | ||
| Q4 24 | 19.2% | -74.3% | ||
| Q3 24 | 22.1% | -94.6% | ||
| Q2 24 | 22.9% | -79.1% | ||
| Q1 24 | 23.3% | -151.9% |
净利率LOARRARE
| Q4 25 | 9.5% | -62.0% | ||
| Q3 25 | 21.8% | -112.8% | ||
| Q2 25 | 13.6% | -69.0% | ||
| Q1 25 | 13.4% | -108.5% | ||
| Q4 24 | 3.3% | -80.9% | ||
| Q3 24 | 8.4% | -95.7% | ||
| Q2 24 | 7.9% | -89.5% | ||
| Q1 24 | 2.4% | -156.8% |
每股收益（稀释后）LOARRARE
| Q4 25 | $0.13 | $-1.28 | ||
| Q3 25 | $0.29 | $-1.81 | ||
| Q2 25 | $0.17 | $-1.17 | ||
| Q1 25 | $0.16 | $-1.57 | ||
| Q4 24 | $-11023.48 | $-1.34 | ||
| Q3 24 | $0.09 | $-1.40 | ||
| Q2 24 | $0.09 | $-1.52 | ||
| Q1 24 | $11023.54 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.8M | $421.0M |
| 总债务越低越好 | $715.7M | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $2.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.61× | — |
8季度趋势，按日历期对齐
现金及短期投资LOARRARE
| Q4 25 | $84.8M | $421.0M | ||
| Q3 25 | $99.0M | $202.5M | ||
| Q2 25 | $103.3M | $176.3M | ||
| Q1 25 | $80.5M | $127.1M | ||
| Q4 24 | $54.1M | $174.0M | ||
| Q3 24 | $55.2M | $150.6M | ||
| Q2 24 | $73.2M | $480.7M | ||
| Q1 24 | $28.2M | $112.3M |
总债务LOARRARE
| Q4 25 | $715.7M | — | ||
| Q3 25 | $279.4M | — | ||
| Q2 25 | $277.7M | — | ||
| Q1 25 | $277.5M | — | ||
| Q4 24 | $277.3M | — | ||
| Q3 24 | $602.1M | — | ||
| Q2 24 | $250.7M | — | ||
| Q1 24 | $534.2M | — |
股东权益LOARRARE
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.1B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.1B | $255.0M | ||
| Q3 24 | $769.8M | $346.8M | ||
| Q2 24 | $758.4M | $432.4M | ||
| Q1 24 | $420.6M | $140.3M |
总资产LOARRARE
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.5B | $1.3B | ||
| Q4 24 | $1.5B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.1B | $1.6B | ||
| Q1 24 | $1.1B | $1.3B |
负债/权益比LOARRARE
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.24× | — | ||
| Q2 25 | 0.25× | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 1.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 2.43× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流LOARRARE
| Q4 25 | $30.4M | $-99.8M | ||
| Q3 25 | $29.7M | $-91.4M | ||
| Q2 25 | $23.8M | $-108.3M | ||
| Q1 25 | $28.4M | $-166.5M | ||
| Q4 24 | $20.7M | $-79.3M | ||
| Q3 24 | $16.3M | $-67.0M | ||
| Q2 24 | $7.1M | $-77.0M | ||
| Q1 24 | $10.8M | $-190.7M |
自由现金流LOARRARE
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率LOARRARE
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度LOARRARE
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率LOARRARE
| Q4 25 | 2.43× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.85× | — | ||
| Q4 24 | 5.62× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 4.81× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
